Plus Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Plus Therapeutics generated cash of -$12,851,000, which is more than the previous year. Cash used in financing activities reached the amount of $3,445,000 last year. Net change in cash is therefore -$9,566,000.
Cash Flow
| 2014 | -30.33M | -1.34M | 30.87M |
|---|---|---|---|
| 2015 | -20.46M | -613K | 20.79M |
| 2016 | -19.53M | 64K | 17.60M |
| 2017 | -18.12M | -1.70M | 16.81M |
| 2018 | -11.97M | -133K | 7.16M |
| 2019 | -5.90M | 5.57M | 12.63M |
| 2020 | -8.43M | -493K | -319K |
| 2021 | -10.28M | -82K | 20.41M |
| 2022 | -12.97M | -759K | 13.45M |
| 2023 | -12.85M | -160K | 3.44M |
PSTV Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 18.12M | 18.4M | 8.34M | 17.59M | 5.30M | 10.22M | 12.56M | 14.33M | 14.62M | 15.50M |
Operating activities | ||||||||||
Net income | -13.31M | -20.27M | -13.39M | -8.24M | -10.88M | -12.63M | -22.68M | -22.04M | -18.74M | -37.36M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 628K | 619K | 395K | 366K | 896K | 2.00M | 2.15M | 1.18M | 1.09M | 779K |
Stock-based compensation expense | 569K | 606K | 606K | 247K | 127K | 0 | 753K | 1.08M | 2.04M | 3.10M |
| Deferred income tax benefit | 569K | 606K | 606K | 247K | 127K | 0 | 753K | 1.08M | 2.04M | 3.10M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 1.16M | -1.20M | -173K | 1.12M | -179K | 328K | 2.05M |
Inventories | 0 | 0 | 0 | 107K | 259K | 475K | 251K | 471K | 490K | -815K |
Accounts payable | -3.67M | 6.45M | 1.73M | -1.23M | -23K | -1.42M | -1.81M | -673K | 771K | -1.14B |
Cash generated by operating activities | -12.85M | -12.97M | -10.28M | -8.43M | -5.90M | -11.97M | -18.12M | -19.53M | -20.46M | -30.33M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -160K | -509K | -144K | -493K | -67K | -133K | -1.49M | -67K | -624K | -1.01M |
Acquisitions Net | 0 | -250K | 62K | -400K | 5.63M | 0 | 113K | 131K | 11K | 0 |
Cash generated by investing activities | -160K | -759K | -82K | -493K | 5.57M | -133K | -1.70M | 64K | -613K | -1.34M |
Financing activities | ||||||||||
Common Stock Issued | 5.52M | 15.05M | 18.67M | 4.00M | 15.96M | 0 | 21.53M | 21.46M | 29.05M | 19.08M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -75K | 0 |
Repurchases of common stock | -126K | 0 | 0 | 0 | 0 | 0 | -2.07M | -2.08M | 0 | -1.55M |
Repayments of term debt | -1.60M | -1.60M | -276K | -5.42M | -3.82M | 0 | -4.72M | 0 | -7.33M | -1.96M |
Cash used in financing activities | 3.44M | 13.45M | 20.41M | -319K | 12.63M | 7.16M | 16.81M | 17.60M | 20.79M | 30.87M |
Net Change In Cash | -9.56M | -280K | 10.05M | -9.24M | 12.29M | -4.92M | -3.01M | -1.77M | -284K | -884K |
Cash at end of period | 8.55M | 18.12M | 18.4M | 8.34M | 17.59M | 5.30M | 9.55M | 12.56M | 14.33M | 14.62M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |